DOI: 10.37990/medr.1309886 ISSN:

lncRNA MALAT1, MEG3, and PANDAR Levels may be Potential Diagnostic Biomarkers in Multiple Myeloma

Elvin ERÖKSÜZ ÖZDİNÇ, Kuyaş HEKİMLER ÖZTÜRK, Fadime MUTLU İÇDUYGU, Demircan ÖZBALCI
  • Colloid and Surface Chemistry
  • Physical and Theoretical Chemistry
Show PDF Cite
Aim: Long non-coding RNAs (lncRNAs) are involved in the pathogenesis of many diseases, including cancer, and have the potential to serve as diagnostic and prognostic markers. Their working mechanism in the development and progression of multiple myeloma (MM) and their role as diagnostic markers are still unclear. This study was designed to reveal the role of cell-free lncRNA in the pathogenesis of MM, its relationship with clinical parameters, and the potential utility of these molecules as biomarkers for the diagnosis of MM. Materials and Methods: Patients over 18 years of age, diagnosed with MM according to the diagnostic criteria established by the International Myeloma Study Group (IMWG), and who had not yet received treatment were enrolled in the study. The expression profiles of the three lncRNA candidates (MALAT1, PANDAR, MEG3), regulated by the p53 gene, were established in the plasma samples of 19 patients with MM and 20 healthy volunteers. Analyses were performed by real-time PCR (qRT-PCR), using cDNAs synthesized from plasma RNAs. Results: Significantly downregulated lncRNA levels in plasma were observed in the patient group (P0.05). A negative correlation was observed between the expression levels of MALAT1, PANDAR, MEG3, and serum albumin level (respectively, r=-0.373, P=0.019; r=-0.318, P=0.048; r=-0.342, P=0.033), which was not associated with other clinicopathological characteristics (P>0.05). The ROC analysis showed that the expression levels of MALAT1, PANDAR, and MEG3 in plasma had diagnostic value in predicting MM (respectively, AUC=0.729, P=0.015; AUC=0.742, P=0.010; AUC=0.703, P=0.031). Conclusion: Consequently, circulating lncRNAs detectable in plasma and MALAT1, PANDAR, and MEG3 may serve as novel biomarkers in MM patients. In addition, these molecules could be a potential drug target.

More from our Archive